Yes. It would suggest my concern about responding DCVax patients eventing early (for PFS) is wrong.
That would still leave open the alternative that the long lived patients in the P1 trials were psPD (and not showing MRI changes due to a beneficial effect of DCVax). In such a case the HR would be 1.0.
How could the HR be 1 yet the 248 hit in November (implying a very long blended mPFS for both arms)?